Rho kinase (ROCK) inhibitors represent a promising neuroprotective approach for Parkinson's Disease that targets multiple pathological pathways simultaneously. While a general therapeutic page for ROCK inhibitors in neurodegeneration exists, this dedicated PD page addresses the growing body of evidence specifically supporting ROCK inhibition in Parkinson's Disease, including active clinical trials.
The ROCK inhibitors Fasudil and its oral derivative RKI have shown remarkable preclinical efficacy in PD models, leading to the ROCK-PD clinical trial (NCT05931575) currently recruiting in Germany.
The Rho-associated coiled-coil containing protein kinase (ROCK) pathway plays a central role in regulating cytoskeletal dynamics, cell contractility, and inflammatory responses. In PD, ROCK is hyperactivated through multiple mechanisms:
flowchart TD
Aα-Synuclein["Aα-Synuclein<br/>Aggregation"] --> B["ROCK Activation"]
C["Oxidative Stress"] --> B
D["Mitochondrial<br/>Dysfunction"] --> B
E["Neuroinflammation"] --> B
B --> F["Cytoskeletal<br/>Dysregulation"]
B --> G["Microglial<br/>Activation"]
B --> H["Impaired<br/>Autophagy"]
B --> I["Neurite<br/>Degeneration"]
F --> J["Axonal<br/>Retraction"]
G --> K["Pro-inflammatory<br/>Cytokine Release"]
H --> L["Protein<br/>Aggregation"]
I --> M["Dopaminergic<br/>Neuron Loss"]
style B fill:#ffcdd2,stroke:#333
style M fill:#ffcdd2,stroke:#333
-
Cytoskeletal Dysregulation: ROCK hyperactivation leads to excessive actin-myosin contraction, impairing axonal transport and neurite stability
-
Microglial Activation: ROCK2 specifically regulates microglial morphology and inflammatory cytokine production (TNF-α, IL-1β, IL-6)
-
Autophagy Impairment: ROCK inhibits autophagy through mTOR activation and Beclin1 phosphorylation, reducing clearance of α-synuclein aggregates
-
Mitochondrial Dysfunction: ROCK activation directly impairs mitochondrial dynamics and promotes fission over fusion
-
Neurite Degeneration: ROCK-mediated cytoskeletal collapse contributes to axonal degeneration preceding cell death
- Post-mortem studies show increased ROCK activity in substantia nigra of PD patients
- Elevated ROCK substrate (MLC phosphorylation) in PD brain tissue
- Genetic association studies suggest ROCK pathway polymorphisms modify PD risk
- MPTP and 6-OHDA models show robust ROCK activation
Fasudil is the most extensively studied ROCK inhibitor for PD:
- Mechanism: Selective ROCK1/2 inhibition (Kd ~ 0.5 μM)
- Properties: Small molecule, blood-brain barrier permeable
- Clinical history: Approved in Japan since 1995 for cerebral vasospasm
- Safety: Well-established safety profile in thousands of patients
- Key preclinical findings:
- Protects dopaminergic neurons from MPTP toxicity[@feng2019]
- Reduces neuroinflammation in LPS models[@chen2020]
- Attenuates α-synuclein aggregation[@liu2021]
- Promotes neurite outgrowth in vitro[@wang2018]
- Improves motor function in 6-OHDA rats[@yan2019]
An oral derivative of fasudil with enhanced CNS penetration:
- Development: Advanced for PD clinical trials
- Advantage: Better bioavailability for chronic dosing
- Status: Under evaluation in ROCK-PD trial[@nct05931575]
- Use: Primarily research tool
- Limitations: Less stable, requires high concentrations
| Compound |
Selectivity |
Development Stage |
| Ripasudil |
ROCK1/2 |
Approved (glaucoma) |
| Netarsudil |
ROCK1/ROCK4 |
Approved (glaucoma) |
| KD025 (Rocogonium) |
ROCK2 |
Phase 2 (fibrosis) |
| Model |
Compound |
Outcome |
Reference |
| MPTP mice |
Fasudil |
↓ TH+ neuron loss, ↓ motor deficits |
[@feng2019] |
| 6-OHDA rats |
Fasudil |
Improved rotational behavior |
[@yan2019] |
| α-synuclein Tg |
Fasudil |
↓ α-syn aggregation, improved cognition |
[@liu2021] |
| LPS rats |
Fasudil |
↓ TNF-α, ↓ IL-1β, protected neurons |
[@chen2020] |
| Rotenone model |
Fasudil |
↓ mitochondrial ROS, preserved ATP |
[@petz2022] |
flowchart LR
subgraph "ROCK Inhibition"
A["Fasudil"] --> B["ROCK1/2 Blockade"]
end
subgraph "Downstream Effects"
B --> C["Cytoskeletal<br/>Relaxation"]
B --> D["Microglial<br/>Modulation"]
B --> E["Autophagy<br/>Enhancement"]
B --> F["Mitochondrial<br/>Protection"]
end
C --> C1["Neurite<br/>Outgrowth"]
C --> C2["Axonal<br/>Transport"]
D --> D1["↓ TNF-α"]
D --> D2["↓ IL-1β"]
D --> D3["M2 Phenotype"]
E --> E1["↑ Beclin1"]
E --> E2["↓ mTOR"]
E --> E3["α-Syn<br/>Clearance"]
F --> F1["↓ ROS"]
F --> F2["Dynamic<br/>Balance"]
F --> F3["ATP<br/>Preservation"]
C1 --> G["Dopaminergic<br/>Neuron Survival"]
C2 --> G
D --> G
E --> G
F --> G
style A fill:#e1f5fe,stroke:#333
style G fill:#c8e6c9,stroke:#333
A landmark Phase IIa trial evaluating fasudil in early Parkinson's Disease:
| Parameter |
Details |
| Status |
Recruiting |
| Sponsor |
Technical University of Munich |
| Phase |
Phase IIa |
| Design |
Double-blind, randomized, placebo-controlled |
| Intervention |
Fasudil hydrochloride, oral, twice daily |
| Dosages |
Two dose levels vs. placebo |
| Duration |
3 weeks treatment |
| Enrollment |
75 early PD patients |
| Centers |
Up to 15 sites in Germany |
| Primary endpoints |
Safety, tolerability |
| Secondary endpoints |
Motor symptoms (MDS-UPDRS) |
Fasudil's established safety profile from 30+ years of clinical use in Japan makes it an attractive candidate for repurposing:
- Established safety: Over 1 million patients treated for cerebral vasospasm
- Known PK/PD: Well-characterized pharmacokinetics
- BBB penetration: Demonstrated CNS distribution
- Multiple mechanisms: Addresses core PD pathologies
- Potential disease-modification: Beyond symptomatic relief
- Disease-modifying potential: Targets upstream pathology rather than just symptoms
- Multi-target approach: Addresses neuroinflammation, protein aggregation, cytoskeletal dysfunction simultaneously
- Repurposing advantage: Known safety profile accelerates clinical development
- Combination potential: Synergistic with dopaminergic therapies
- Neuro-regenerative effects: Promotes neurite outgrowth
ROCK inhibitors may be particularly effective in combination:
| Combination |
Rationale |
Potential Benefit |
| ROCKi + L-DOPA |
Symptomatic + neuroprotective |
Enhanced durability |
| ROCKi + GLP-1 RA |
Complementary mechanisms |
Disease modification |
| ROCKi + CoQ10 |
Mitochondrial support |
Synergistic protection |
| ROCKi + Anti-α-syn |
Aggregation reduction |
Enhanced clearance |
¶ Challenges and Future Directions
- Optimal dosing: Balancing efficacy with potential hypotension
- Chronic treatment: Long-term safety in elderly PD population
- Biomarkers: Need markers to track target engagement
- Patient selection: Identifying responders
- Delivery: Ensuring consistent CNS exposure
- ROCK2-selective inhibitors: Potentially better safety profile
- Novel derivatives: Improved CNS penetration
- Protein kinase inhibitors: Broader kinase inhibition (fasudil also inhibits PKC, MLCK at higher doses)
- Topical formulations: For specific symptom targeting
- Teschendorf P, et al., ROCK inhibition as a therapeutic target in Parkinson's disease (2019)
- Feng Y, et al., Fasudil protects dopaminergic neurons in a rat model of Parkinson's disease (2019)
- Chen M, et al., ROCK inhibition reduces neuroinflammation in Parkinson's disease models (2020)
- Liu W, et al., Rho-kinase inhibition attenuates alpha-synuclein aggregation in PD models (2021)
- Wang Y, et al., ROCK inhibitors promote neurite outgrowth and dopaminergic differentiation (2018)
- Yan B, et al., Fasudil ameliorates MPTP-induced motor deficits in mice (2019)
- Zhou Y, et al., ROCK2 inhibition attenuates microglial activation and neuroinflammation (2022)
- Petz S, et al., Rho-kinase inhibition protects against mitochondrial dysfunction in PD (2022)
- NCT05931575: Fasudil for Parkinson Disease
- Ishizaki T, et al., The Rho-kinase inhibitor Y-27632 relaxes rabbit aortic smooth muscle (2000)
- Uehata M, et al., Calcium sensitization of smooth muscle mediated by Rho-associated kinase (1997)
- Satoh S, et al., Fasudil hydrochloride in the treatment of cerebral vasospasm (2011)